secwatch.observer — SEC 8-K summary
======================================

Issuer:     FILANA THERAPEUTICS, INC. (FLNA)
CIK:        0001069530
Form:       8-K
Filed at:   2024-07-01T23:59:59+00:00
Accession:  0001493152-24-025725
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Cassava discloses potential unblinding in Phase 2b study; collaborator indicted by DOJ
--------------------------------------------------------------------------------

- DOJ indicted Dr. Wang for allegedly causing false statements to NIH about simufilam; company terminated his consulting.
- Internal investigation found senior employee may have unblinded Dr. Wang to some Phase 2b participants before bioanalysis.
- Reported Phase 2b CANTAB analysis excluded ~42% of subjects for episodic memory; results reflect smaller analysis set.
- Phase 3 trials fully enrolled (~1,900 patients), remain blinded; independent firms will handle bioanalysis.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1069530/000149315224025725/0001493152-24-025725-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1069530/000149315224025725/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-025725

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer